Ratings Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Delayed Japan Exchange 02:00:00 2024-06-24 EDT 5-day change 1st Jan Change
4,095 JPY +1.66% Intraday chart for Takeda Pharmaceutical Company Limited -1.13% +1.01%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • One of the major weak points of the company is its financial situation.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.3 times its estimated earnings per share for the ongoing year.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+1.01% 39.61B
B+
+52.70% 796B
C+
+41.58% 628B
B
-4.86% 358B
C+
+21.96% 331B
B-
+11.47% 301B
C+
+17.72% 244B
B+
+4.46% 228B
A+
+13.13% 214B
B-
+10.46% 165B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. Ratings Takeda Pharmaceutical Company Limited